Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about REGN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dupilumab FDA approved Mar 2017 · Dupixent |
Atopic Dermatitis | Phase 4 · NCT05268107 | Recruiting |
| Pozelimab FDA approved Aug 2023 · Veopoz |
Age-related Macular Degeneration (AMD) | Phase 3 · NCT06541704 | Recruiting |
| Cemiplimab FDA approved Sep 2018 · Libtayo |
Melanoma | Phase 3 · NCT06246916 | Recruiting |
| Freneslerbart | Allergic Conjunctivitis | Phase 3 · NCT07675811 | Recruiting |
| Mevonlerbart | Allergic Conjunctivitis | Phase 3 · NCT07675811 | Recruiting |
| Mibavademab | Monogenic Obesity | Phase 3 · NCT07220772 | Recruiting |
| Aspirin | Symptomatic Venous Thromboembolism (VTE) | Phase 3 · NCT07213778 | Recruiting |
| Odronextamab | Follicular Lymphoma (FL) | Phase 3 · NCT06091254 | Recruiting |
| Lipid Nanoparticle Encapsulating mRNA Encoding… | Neuromuscular Disease | Phase 3 · NCT06672237 | Active not recruiting |
| Prednisolone | Follicular Lymphoma (FL) | Phase 3 · NCT06091254 | Recruiting |
| REGN-2Cat | Allergic Conjunctivitis | Phase 3 · NCT07675811 | Recruiting |
| Cenvacibart (REGN7508) | Peripheral Artery Disease (PAD) | Phase 3 · NCT07318610 | Recruiting |
| Amrecibart (REGN9933) | Peripheral Artery Disease (PAD) | Phase 3 · NCT07318610 | Recruiting |
| Vincristine | Follicular Lymphoma (FL) | Phase 3 · NCT06091254 | Recruiting |
| Fianlimab | Melanoma | Phase 3 · NCT06246916 | Recruiting |
| Bendamustine | Follicular Lymphoma (FL) | Phase 3 · NCT06091254 | Recruiting |
Also used in these trials (approved or third-party drugs, not REGN's own candidates): Pomalidomide, Gemcitabine Hydrochloride, Lenalidomide, Linvoseltamab, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Prednisone, Ravulizumab, Relatlimab, Rituximab, Rivaroxaban.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
REGN holds $18.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 8,849,583 | 9.42% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 7,660,810 | 8.15% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 4,881,362 | 5.20% | 2026-09-30 |
| Dodge & Cox Inc. | Institution (13F) | 4,774,489 | 5.08% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 3,721,270 | 3.96% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 3,307,392 | 3.52% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 3,111,677 | 3.31% | 2026-09-30 |
| Franklin Resources, Inc. | Institution (13F) | 2,950,805 | 3.14% | 2026-09-30 |
| Franklin Templeton, Inc. | Institution (13F) | 2,950,805 | 3.14% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 2,632,826 | 2.80% | 2026-09-30 |
| Nuveen, LLC | Institution (13F) | 1,955,949 | 2.08% | 2026-09-30 |
| George Yancopoulos Bd. Co-Chair, President & CSO, Director · +595,077 options |
Insider | 1,125,945 | 1.20% | 2025-12-31 |
Share count 93,955,110 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-04 filed 2026-11-06 |
Pitofsky Jason |
Option exercise (M) | 1,500 | $726.53 | 5,772 |
| 2026-11-04 filed 2026-11-06 |
Pitofsky Jason |
Option exercise (M) | 1,500 | – | – |
| 2026-11-04 filed 2026-11-06 |
Pitofsky Jason |
Option exercise (M) | 1,478 | – | – |
| 2026-11-04 filed 2026-11-06 |
Pitofsky Jason |
Option exercise (M) | 905 | – | – |
| 2026-11-04 filed 2026-11-06 |
Pitofsky Jason |
Sale (S) | 179 | $950.76 | 0 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →